Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Stopped The federal funding period ended. The study was originally intended to be multi-site but was only conducted at the lead site. Due to the rarity of the subject population \& smaller # of enrolling sites, we were not able to reach accrual goals.
Conditions
- Acute Erythroid Leukemia
- Acute Lymphoblastic Leukemia
- Acute Megakaryoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Hematopoietic and Lymphoid Cell Neoplasm
- HIV Infection
- Myelodysplastic Syndrome
- Myelodysplastic Syndrome With Excess Blasts
- Non-Hodgkin Lymphoma
- Refractory Anemia
Interventions
- DRUG: Fludarabine
- DRUG: Cyclophosphamide
- DRUG: Thiotepa
- RADIATION: Total-Body Irradiation
- PROCEDURE: Umbilical Cord Blood Transplantation
- BIOLOGICAL: Dilanubicel
Sponsor
Fred Hutchinson Cancer Center
Collaborators